Strategic partnerships Private clinical-stage biotech with FDA Breakthrough Designations and a growing Series B funding trajectory presents opportunities to partner with large pharma for co-development, manufacturing partnerships, or global licensing deals to scale late-stage trials and commercialization.

Intratumoral platform Unique intratumoral delivery approach for tumoricidal therapies with reduced off-target effects can be positioned as a differentiator to engage oncology-focused CDMOs, contract manufacturers, and hospital systems seeking localized cancer treatments.

Breast cancer focus Pipeline targets metastatic and primary breast cancer with bone, liver metastases, and neo-adjuvant strategies, creating cross-sell opportunities with oncology product portfolios, bone health franchises, and radiology/interventional oncology partnerships.

Clinical momentum Phase 2a results and ongoing Phase 1b/planned studies, supported by NIH/NCI funding and peer-reviewed publications, offer a credible pathway for sales discussions with academic medical centers, disease-focused foundations, and payer pilots.

Funding signals Recent Series A/B financing and strategic backing from Excell Partners indicate investor confidence and potential for co-investment conversations, enabling joint funding programs, access to venture networks, and accelerated market entry planning.